<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768261</url>
  </required_header>
  <id_info>
    <org_study_id>5R01MH060883-06</org_study_id>
    <nct_id>NCT00768261</nct_id>
  </id_info>
  <brief_title>Corticolimbic Degeneration and Treatment of Dementia</brief_title>
  <official_title>Corticolimbic Degeneration and Treatment of Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this research is to determine if there is a relationship between your
      symptoms of Dementia of the Alzheimers type and changes in the size and shape of certain
      brain structures during combined Donepezil (Aricept®) and Memantine (Namenda®) treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will be using Memantine (Namenda®) in an investigational fashion with
      individuals with very mild to mild dementia. Donepezil (Aricept®) is approved by the Food and
      Drug Administration for the treatment of Alzheimers disease. Memantine (Namenda®) is
      currently approved by the Food and Drug Administration for moderate and severe dementia only.
      This study may be instrumental in the development of a new therapy for others with similar
      conditions, and to determine whether Memantine (Namenda®) will be helpful to individuals with
      very mild to mild dementia.

      Specific Aim 1. To determine what neuroanatomical measures are most strongly correlated with
      the progression of clinical and cognitive deficits in patients with dementia of the Alzheimer
      type (DAT). To accomplish this aim, we will use high-resolution magnetic resonance (MR)
      imaging and the tools of computational anatomy to assess changes in the structure of selected
      subcortical (e.g., hippocampus) and cortical (e.g., parahippocampal gyrus and cingulate
      gyrus) structure along with clinical and cognitive measures of dementia severity in subjects
      with very mild-to-mild DAT. Specific Aim 2 - To determine whether cholinesterase inhibitors
      and memantine can slow disease progression in DAT subjects. To accomplish this aim, we will
      use MR imaging and the tools of computational anatomy to compare the rate of change in the
      neuroanatomical measures listed above in 1) untreated DAT subjects, 2) DAT subjects treated
      with donepezil alone, and 3) DAT subjects treated with the combination of donepezil and
      memantine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Change of Hippocampal Volume Slope</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change</measure>
    <time_frame>two years</time_frame>
    <description>The ADAS-Cog evaluates cognition and differentiates normal from impaired cognitive functioning. The total score is the summed number of errors in each task. The greater the impairment, the greater the score. We combined the dementia of the Alzheimer's type patients receiving all treatments together and grouped them into 3 subgroups according to the rates of change(roc) of their ADAS-Cog scores. To determine trends in hippocampal volume atrophy over time we compared the patients showing most negative ADAS-Cog rate of change (improving), patients with most positive ADAS-cog roc (worsening), patients with intermediate, near-zero ADAS-Cog roc (stable) .</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Very Mild to Mild DAT Untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very Mild-Mild DAT Treated W/ Donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very Mild-Mild DAT Treated W/Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nondemented Comparison Subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 4) nondemented comparison subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine (Namenda®)</intervention_name>
    <description>Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.</description>
    <arm_group_label>Very Mild-Mild DAT Treated W/Combination</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil (Aricept®)</intervention_name>
    <description>5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.</description>
    <arm_group_label>Very Mild-Mild DAT Treated W/ Donepezil</arm_group_label>
    <arm_group_label>Very Mild-Mild DAT Treated W/Combination</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 1) meets National Institute of Neurological and Communicative Disorders
        and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA)
        Alzheimer's criteria for dementia of the Alzheimer's type (DAT), 2) Clinical Dementia
        Rating (CDR) score of 0.5 or 1, 3) 50-80 years of age, 4) able to give informed consent or
        has a primary caregiver or legal guardian, who can give informed consent.

        Exclusion Criteria: 1) other psychiatric (e.g., depression) or neurological (e.g., CVA)
        disorders that would confound the assessment of dementia symptoms, 2) history of loss of
        consciousness, and 3) unstable or severe medical illness (e.g., hepatotoxicity) that would
        make donepezil or memantine treatment or participation in other aspects of the study
        unsafe.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <results_first_submitted>April 24, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2018</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia of the Alzheimer type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT00768261/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>39 subjects enrolled in Group3.14 maps have passed inspection for quality and are included in final analysis. Subject data from a previously published study of donepezil(Wang et al.,2010) with 18 very mild dementia of the Alzheimer's type patients treated with donepezil,14 untreated with mild DAT, and 56 cognitively normal individuals are included.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Very Mild to Mild DAT Untreated</title>
          <description>Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine</description>
        </group>
        <group group_id="P2">
          <title>2 Very Mild to Mild DAT Treated With Donepezil</title>
          <description>Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with donepezil.
Donepezil (Aricept®): 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.</description>
        </group>
        <group group_id="P3">
          <title>3 Very Mild to Mild DAT Treated With the Combination</title>
          <description>Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of donepezil and memantine.
Memantine (Namenda®): Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Memantine (Namenda®): Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects</description>
        </group>
        <group group_id="P4">
          <title>4 Nondemented Comparison Subjects.</title>
          <description>Group 4) nondemented comparison subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Group 3; 39 subjects initially included. 8 subjects ineligible at initial assessment. 8 didn't have a follow-up MR scans for reasons; being deceased at the eos, refusal to scan, being unable to complete scanning due to discomfort. 5 subjects excluded due to poor baseline MR quality. 4 more scans excluded due to poor longitudinal mapping quality</population>
      <group_list>
        <group group_id="B1">
          <title>1 Very Mild to Mild DAT Untreated</title>
          <description>Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine</description>
        </group>
        <group group_id="B2">
          <title>2 Very Mild to Mild DAT Treated With Donepezil</title>
          <description>Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with donepezil.
Donepezil (Aricept®): 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.</description>
        </group>
        <group group_id="B3">
          <title>3 Very Mild to Mild DAT Treated With the Combination</title>
          <description>Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of donepezil and memantine.
Memantine (Namenda®): Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Memantine (Namenda®): Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects</description>
        </group>
        <group group_id="B4">
          <title>4 Nondemented Comparison Subjects.</title>
          <description>Group 4) nondemented comparison subjects.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change of Hippocampal Volume Slope</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Very Mild to Mild DAT Untreated</title>
            <description>Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine</description>
          </group>
          <group group_id="O2">
            <title>2 Very Mild to Mild DAT Treated With Donepezil</title>
            <description>Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with donepezil.
Donepezil (Aricept®): 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.</description>
          </group>
          <group group_id="O3">
            <title>3 Very Mild to Mild DAT Treated With the Combination</title>
            <description>Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of donepezil and memantine.
Memantine (Namenda®): Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Memantine (Namenda®): Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects</description>
          </group>
          <group group_id="O4">
            <title>4 Nondemented Comparison Subjects.</title>
            <description>Group 4) nondemented comparison subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change of Hippocampal Volume Slope</title>
          <units>mm^3/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>left hippocampal volume slope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.2418748" spread="31.4801034"/>
                    <measurement group_id="O2" value="-88.4738591" spread="52.2621175"/>
                    <measurement group_id="O3" value="-94.0768115" spread="48.349487"/>
                    <measurement group_id="O4" value="-46.9484805" spread="83.5825530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hippocampal volume slope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-99.9437062" spread="65.1619838"/>
                    <measurement group_id="O2" value="-94.3258652" spread="44.7959659"/>
                    <measurement group_id="O3" value="-125.0687876" spread="72.5509442"/>
                    <measurement group_id="O4" value="-80.0840066" spread="130.3453711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>ANOVA</method>
            <method_desc>df= 3,92</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change</title>
        <description>The ADAS-Cog evaluates cognition and differentiates normal from impaired cognitive functioning. The total score is the summed number of errors in each task. The greater the impairment, the greater the score. We combined the dementia of the Alzheimer's type patients receiving all treatments together and grouped them into 3 subgroups according to the rates of change(roc) of their ADAS-Cog scores. To determine trends in hippocampal volume atrophy over time we compared the patients showing most negative ADAS-Cog rate of change (improving), patients with most positive ADAS-cog roc (worsening), patients with intermediate, near-zero ADAS-Cog roc (stable) .</description>
        <time_frame>two years</time_frame>
        <population>We combined the DAT patients who received any treatment (donepezil or combined) &amp; used the annual roc in ADAS-Cog to equally separate them into 3 subgroups; improving (1/3 negative ADAS-Cog roc), stable (1/3 near-zero ADAS-Cog change) &amp; worsening (1/3 positive ADAS-Cog change).</population>
        <group_list>
          <group group_id="O1">
            <title>Improved</title>
            <description>Response group by ADAS-Cog rates</description>
          </group>
          <group group_id="O2">
            <title>Worsening</title>
            <description>Response group by ADAS-Cog rates</description>
          </group>
          <group group_id="O3">
            <title>Stable</title>
            <description>Response group by ADAS-Cog rates</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change</title>
          <description>The ADAS-Cog evaluates cognition and differentiates normal from impaired cognitive functioning. The total score is the summed number of errors in each task. The greater the impairment, the greater the score. We combined the dementia of the Alzheimer's type patients receiving all treatments together and grouped them into 3 subgroups according to the rates of change(roc) of their ADAS-Cog scores. To determine trends in hippocampal volume atrophy over time we compared the patients showing most negative ADAS-Cog rate of change (improving), patients with most positive ADAS-cog roc (worsening), patients with intermediate, near-zero ADAS-Cog roc (stable) .</description>
          <population>We combined the DAT patients who received any treatment (donepezil or combined) &amp; used the annual roc in ADAS-Cog to equally separate them into 3 subgroups; improving (1/3 negative ADAS-Cog roc), stable (1/3 near-zero ADAS-Cog change) &amp; worsening (1/3 positive ADAS-Cog change).</population>
          <units>(mm^3/year)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>left hippocampal volume slope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70" spread="56"/>
                    <measurement group_id="O2" value="-106" spread="55"/>
                    <measurement group_id="O3" value="-100" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hippocampal volume slope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77" spread="51"/>
                    <measurement group_id="O2" value="-141" spread="78"/>
                    <measurement group_id="O3" value="-105" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>There would be a treatment effect on the changes of hippocampal measures over time.
Repeated measures ANOVA on hippocampal volume slopes with hemisphere as a within-subject repeated factor, and treatment group as the main effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There would be a treatment effect on the changes of hippocampal measures over time.
Repeated measures ANOVA on hippocampal volume slopes with hemisphere as a within-subject repeated factor, and treatment group as the main effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>There would be a treatment effect on the changes of hippocampal measures over time.
Repeated measures ANOVA on hippocampal volume slopes with hemisphere as a within-subject repeated factor, and treatment group as the main effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>RM-ANOVA on hippocampal volume slope</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Very Mild to Mild DAT Untreated</title>
          <description>Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine</description>
        </group>
        <group group_id="E2">
          <title>2 Very Mild to Mild DAT Treated With Donepezil</title>
          <description>Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with donepezil.
Donepezil (Aricept®): 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.</description>
        </group>
        <group group_id="E3">
          <title>3 Very Mild to Mild DAT Treated With the Combination</title>
          <description>Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of donepezil and memantine.
Memantine (Namenda®): Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Memantine (Namenda®): Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects</description>
        </group>
        <group group_id="E4">
          <title>4 Nondemented Comparison Subjects.</title>
          <description>Group 4) nondemented comparison subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interpretation of results limited to evaluating overall effects in naturalistic groups undergoing 2 drug treatments;Insufficient subjects to determine possible existence of DAT patient subgroups showing drug-specific slowing of disease progression</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John G. Csernansky, MD</name_or_title>
      <organization>Washington University</organization>
      <phone>(312) 926-2323</phone>
      <email>jgc@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

